Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(11):1447–1452. doi: 10.1054/bjoc.2001.1817

A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom

R J Sambrook 1, D J Girling 1
PMCID: PMC2363653  PMID: 11384091

Abstract

Many chemotherapy regimens are used for treating SCLC in the United Kingdom, but it is not known, in any detail, which regimens are used, by which specialists, for which types of patient. We conducted a survey among all medical and clinical oncologists, respiratory physicians and general physicians with respiratory interest in the United Kingdom to find out. The questionnaire asked for the number of SCLC patients treated annually; how many were given chemotherapy; the drugs, doses and schedules chosen according to prognostic group (as defined by the clinician); and the reasons for choice of regimen. 1214 questionnaires were sent out, and responses were received from 1070 (88%) clinicians; 266 (25%) of these treated SCLC with chemotherapy. Of 4674 patients given chemotherapy annually, 36% were given it by clinical oncologists, 30% by medical oncologists, 27% by respiratory physicians, and 7% by general physicians. In all, 34 regimens were reported with 151 different combinations of dose and schedule. In 2311 good prognosis patients, 23 regimens were used, the commonest being ACE (doxorubicin, cyclophosphamide, etoposide), ICbE (ifosfamide, carboplatin, etoposide), CAV (cyclophosphamide, doxorubicin, vincristine), CbE (carboplatin, etoposide), and PE (cisplatin, etoposide). In 1517 poor prognosis patients, 21 regimens were used, the commonest being CAV, EV (etoposide, vincristine), CbE, CAV alternating with PE, and oral etoposide. 452 patients were treated regardless of prognosis and for 219 no prognostic criteria were specified. The remaining 175 were given second-line chemotherapy or were given regimens chosen to avoid toxicity or because of intercurrent disease or other reasons. The main reasons affecting choice of regimen were routine local practice, patients' convenience, quality of life considerations, trial results and cost. The results show wide variation in routine practice and will be useful in reporting and planning clinical trials and in deciding on local treatment policies. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: small cell lung cancer, chemotherapy, national survey

Full Text

The Full Text of this article is available as a PDF (56.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arriagada R., Le Chevalier T., Pignon J. P., Rivière A., Monnet I., Chomy P., Tuchais C., Tarayre M., Ruffié P. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med. 1993 Dec 16;329(25):1848–1852. doi: 10.1056/NEJM199312163292504. [DOI] [PubMed] [Google Scholar]
  2. Cerny T., Blair V., Anderson H., Bramwell V., Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987 Feb 15;39(2):146–149. doi: 10.1002/ijc.2910390204. [DOI] [PubMed] [Google Scholar]
  3. Cullen M., Morgan D., Gregory W., Robinson M., Cox D., McGivern D., Ward M., Richards M., Stableforth D., Macfarlane A. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol. 1986;17(2):157–160. doi: 10.1007/BF00306746. [DOI] [PubMed] [Google Scholar]
  4. Ettinger D. S. New drugs for treating small cell lung cancer. Lung Cancer. 1995 Jun;12 (Suppl 3):S53–S61. doi: 10.1016/s0169-5002(10)80018-2. [DOI] [PubMed] [Google Scholar]
  5. Giaccone G., Dalesio O., McVie G. J., Kirkpatrick A., Postmus P. E., Burghouts J. T., Bakker W., Koolen M. G., Vendrik C. P., Roozendaal K. J. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1993 Jul;11(7):1230–1240. doi: 10.1200/JCO.1993.11.7.1230. [DOI] [PubMed] [Google Scholar]
  6. Groen H. J., Fokkema E., Biesma B., Kwa B., van Putten J. W., Postmus P. E., Smit E. F. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol. 1999 Mar;17(3):927–932. doi: 10.1200/JCO.1999.17.3.927. [DOI] [PubMed] [Google Scholar]
  7. Murray N. Treatment of small cell lung cancer: the state of the art. Lung Cancer. 1997 Jun;17 (Suppl 1):S75–S89. doi: 10.1016/s0169-5002(97)00641-7. [DOI] [PubMed] [Google Scholar]
  8. Pujol J. L., Carestia L., Daurès J. P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 2000 Jul;83(1):8–15. doi: 10.1054/bjoc.2000.1164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Souhami R. L., Spiro S. G., Rudd R. M., Ruiz de Elvira M. C., James L. E., Gower N. H., Lamont A., Harper P. G. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997 Apr 16;89(8):577–580. doi: 10.1093/jnci/89.8.577. [DOI] [PubMed] [Google Scholar]
  10. Spiro S. G., Souhami R. L., Geddes D. M., Ash C. M., Quinn H., Harper P. G., Tobias J. S., Partridge M., Eraut D. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989 Apr;59(4):578–583. doi: 10.1038/bjc.1989.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Thatcher N., Girling D. J., Hopwood P., Sambrook R. J., Qian W., Stephens R. J. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol. 2000 Jan;18(2):395–404. doi: 10.1200/JCO.2000.18.2.395. [DOI] [PubMed] [Google Scholar]
  12. Turrisi A. T., 3rd, Kim K., Blum R., Sause W. T., Livingston R. B., Komaki R., Wagner H., Aisner S., Johnson D. H. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28;340(4):265–271. doi: 10.1056/NEJM199901283400403. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES